Keyphrases
Phase II Study
100%
Platelet Engraftment
100%
Eltrombopag
100%
Haploidentical Transplantation
100%
Platelet Recovery
50%
Haploidentical Hematopoietic Stem Cell Transplantation
40%
Bone Marrow Graft
30%
Post-transplantation Cyclophosphamide (PTCy)
30%
Confidence Interval
20%
Adverse Events
10%
Platelet Count
10%
Median Time
10%
Disease Rate
10%
Relapse Rate
10%
Non-relapse Mortality
10%
Graft-versus-host Disease (GvHD)
10%
Cumulative Incidence
10%
Improved Outcomes
10%
Between-group
10%
Overall Survival Progression-free Survival
10%
Graft-versus-host Disease Prophylaxis
10%
Thrombopoietin Receptor Agonists (TPO-RAs)
10%
Platelet Transfusion
10%
Matched Control Group
10%
Transfusion Outcomes
10%
Medicine and Dentistry
Engraftment
100%
Platelet
100%
Bone Marrow Transplantation
100%
Eltrombopag
100%
Haploidentical Hematopoietic Stem Cell Transplantation
40%
Cyclophosphamide
30%
Transplantation
30%
Graft Versus Host Reaction
20%
Prospective Study
10%
Overall Survival
10%
Adverse Event
10%
Progression Free Survival
10%
Recurrence Risk
10%
Non-Relapse Mortality
10%
Cumulative Incidence
10%
Prophylaxis
10%
Post-Hoc Analysis
10%
Thrombocyte Transfusion
10%
Thrombopoietin Receptor
10%
Immunology and Microbiology
Engraftment
100%
Platelet
100%
Bone Marrow Transplantation
100%
Haploidentical Hematopoietic Stem Cell Transplantation
50%
Cyclophosphamide
37%
Graft-Versus-Host Disease
25%
Agonist
12%
Platelet Count
12%
Overall Survival
12%
Progression Free Survival
12%
Thrombopoietin Receptor
12%
Agricultural and Biological Sciences
Thrombopoietin Receptor
25%